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Eisenmenger Syndrome
A Clinical Perspective in a New Therapeutic Era
of Pulmonary Arterial Hypertension
Maurice Beghetti, MD,* Nazzareno Galiè, MD†
Geneva, Switzerland; and Bologna, Italy
Eisenmenger syndrome (ES), the most advanced form of pulmonary arterial hypertension (PAH) associated with
congenital heart disease, is a devastating condition that has a considerable impact on patients’ lives. Patients
who develop ES typically exhibit 1 or more of a range of cardiac defects, including ventricular septal defects,
atrial septal defects, and patent ductus arteriosus. The nature of the congenital defect underlying ES is impor-
tant because it has prognostic implications. Although ES shares similar morphological findings with idiopathic
PAH, clinical differences exist between the 2 etiologies. Adults with ES exhibit increased survival and more favor-
able hemodynamics than those with idiopathic PAH. Treatment options for patients with ES have historically
been limited; however, recent successes have been achieved with the use of therapies targeted against the
pathophysiological pathways that underlie PAH. The dual endothelin receptor antagonist bosentan was demon-
strated to improve hemodynamics and exercise capacity without compromising oxygen saturation, both in the
short and long term. Improvements in hemodynamics also have been observed with the single endothelin recep-
tor antagonist sitaxsentan. The phosphodiesterase type V inhibitor sildenafil may improve functional class, oxy-
gen saturation, and hemodynamics in patients with ES, and beneficial effects of prostacyclin and prostacyclin
analogs in patients with ES have been reported. The treatment of patients with PAH with the use of combina-
tions of targeted therapies is becoming increasingly commonplace and may offer an alternative option for treat-
ment of patients with ES. The authors of future studies may seek to investigate whether the pulmonary vascular
remodeling in ES can be targeted and reversed. (J Am Coll Cardiol 2009;53:733–40) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.025i
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nisenmenger syndrome (ES) represents the most advanced
orm of pulmonary arterial hypertension (PAH) associated
ith congenital heart defects (CHD) (1,2). Although pa-
ients with ES frequently survive into their third or fourth
ecades of life, the symptoms of this disease, which include
yspnea, cyanosis, fatigue, dizziness, and syncope, reduce
ife expectancy (3). In addition, cardiac arrhythmias, an
mportant late complication of ES, are a frequent cause of
udden death in patients with ES (4).
During the past 50 years, the prevalence of ES in the
estern world has reduced by an estimated 50%, resulting
rom advances in surgery and pediatric cardiology (4).
linical management of patients with ES has traditionally
ocused on palliative and supportive treatment; however, an
rom the *University Hospital of Geneva, Geneva, Switzerland; and the †University
f Bologna, Bologna, Italy. Prof. Galiè has served on advisory boards for Pfizer,
ctelion, Bayer Schering, Encysive, Myogen, GlaxoSmithKline, Eli Lilly, and
ondobiotech, and has received lecture fees from Actelion and Bayer Schering. Prof.
eghetti has served on advisory boards for Pfizer, Actelion, Bayer Schering, Encysive,
laxoSmithKline, INO Therapeutics, Eli Lilly, and Mondobiotech, and has received
ecture fees from Actelion, Encysive, and Bayer Schering. Dr. Galiè’s Institute has
eceived grant support from Pfizer, Actelion, Bayer Schering, Encysive, United
herapeutics, Eli Lilly, and Myogen.l
Manuscript received August 28, 2008; revised manuscript received November 11,
008, accepted November 16, 2008.ncreased understanding of the pathophysiology of ES and
he success of disease-specific treatment for PAH has
ffered new hope for patients with ES. This review provides
n overview of the pathophysiology and natural history of
S, an evaluation of similarities and differences between ES
nd PAH, and a summary of key data on emerging
reatments.
athophysiology
wide range of cardiac defects can lead to pulmonary
ascular disease, although the lesions most common to ES
re ventricular septal defects (VSDs), atrial septal defects
ASDs), atrioventricular septal defects, and patent ductus
rteriosus (2,4). Approximately 50% of all patients with
arge unrepaired VSDs, approximately 10% of patients with
arge unrepaired ASDs, and almost all patients with unre-
aired truncus arteriosus are at risk of developing ES (5,6).
he underlying defect in ES is important because it has
rognostic implications. Evidence suggests, for example,
hat patients with ASDs differ in their evolution of pulmo-
ary vascular disease compared with patients with VSDs (4).
Patients with ES may present with more complex under-ying lesions, such as truncus arteriosus, transposition of
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PAH in Eisenmenger Syndrome March 3, 2009:733–40great vessels and VSD, or single
ventricles with unobstructed pul-
monary blood flow. The devel-
opment of ES in patients with
complex CHD is associated with
a 10- to 12-fold increase in mor-
tality (6).
Key stages in development of
ES are outlined in Figure 1 (5).
The mechanisms underlying
the remodeling of the cardio-
pulmonary circulation have not
been fully elucidated but are
likely to involve vasoconstric-
tion, inflammation, thrombosis,
cell proliferation, and fibrosis
(7). Implicated in these mech-
nisms is an errant expression of vasoactive mediators,
ncluding endothelin-1, thromboxane, prostacyclin, and
itric oxide (7). The apparent importance of such mole-
ules in the development of ES emphasizes the similar-
ties between this condition and other etiologies of PAH.
he 3 major pathophysiological pathways that represent
mportant signaling cascades in PAH are illustrated in
igure 2 (8).
S Versus Other Forms of PAH
tructural changes in the pulmonary vasculature are quali-
atively similar in all forms of PAH, including ES (9). In the
Abbreviations
and Acronyms
ASD  atrial septal defect
CHD  congenital heart
defects
ES  Eisenmenger
syndrome
IPAH  idiopathic
pulmonary arterial
hypertension
PAH  pulmonary arterial
hypertension
PVR  pulmonary vascular
resistance
VSD  ventricular septal
defect
Figure 1 Key Stages in the
Development of Eisenmenger Syndrome
Reproduced, with permission, from
Vongpatanasin et al. (5). PVR  pulmonary vascular resistance.Eenice classification, PAH associated with CHD (PAH-
HD) is grouped with idiopathic, drug-, connective tissue
isease- and human immunodeficiency virus–related etiol-
gies (10). Notable clinical differences, however, are re-
orted to exist between ES and idiopathic pulmonary
rterial hypertension (IPAH). For example, patients with
S may experience hemoptysis, cerebrovascular incidents,
rain abscesses, secondary erythrocytosis, and coagulation
bnormalities, as well as sudden death, cardiac arrhythmia,
nd other problems associated with insufficient tissue oxy-
enation that are uncommon in IPAH (3,5).
Adult patients with ES exhibit increased survival and a
ore favorable hemodynamic profile and prognosis versus
ntreated patients with IPAH (11). Several vascular differ-
nces between patients with ES and IPAH also have been
eported (12). These differences may result from the initial
reservation of right ventricular function and relief of excess
ressure via the right-to-left shunt. Consequently, patients
ith ES may exhibit better life expectancy but poorer
uality of life in comparison with patients with IPAH.
reatment of ES
istorically, management options for patients with ES have
een limited to palliative measures or heart-lung transplan-
ation, the latter of which is suitable only for a small
ubgroup of patients. Pharmacological treatment often in-
olved the use of digitalis, diuretics, antiarrhythmics, and/or
nticoagulants; however, none of these approaches signifi-
antly modified survival or risk of deterioration (3). Right
eart failure is a potential complication of ES, for which
igoxin may be beneficial, although evidence supporting
his application is weak (13). Digoxin may, however, be of
reater utility in the treatment of arrhythmias. Diuretics
ave been used for symptomatic relief of congestion (5) but
arry the risk of worsening hyperviscosity. A better under-
tanding of the molecular biology underlying right heart
ailure will hopefully reveal novel therapeutic targets for
ight ventricular failure in ES.
The use of anticoagulants in ES is controversial because
f the increased risk of hemoptysis, stroke, and hemorrhage
14). The prevalence of pulmonary artery thrombosis in ES
s estimated to be 20%, with increasing risk correlating with
ncreasing age, biventricular dysfunction, dilation of the
ulmonary arteries, and concomitantly decreased pulmonary
ow velocity (15). Although the use of anticoagulants may
e beneficial in patients with IPAH, no prospective studies
ave addressed their value in ES; therefore, no recommen-
ations for their use can be given.
Patients with long-standing cyanosis may develop bron-
hial collaterals that lead to hemoptysis. Our own experi-
nce in treating chronic thromboembolic pulmonary hyper-
ension and ES suggests that percutaneous closure of these
essels may be a potential therapeutic option in ES.
The efficacy of calcium-channel blockers in patients with
S is neither proven nor recommended because their use
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March 3, 2009:733–40 PAH in Eisenmenger Syndromeay decrease systemic arterial pressure and increase right-
o-left shunting, leading to syncope and sudden death (5).
ong-term therapy with oxygen administered for at least 12
o 15 h/day may improve symptoms but has not been shown
o influence survival (14). Tailored oxygen therapy is indi-
ated if there is evidence of significant desaturation.
Phlebotomy with isovolumic replacement is used in the
anagement of hyperviscosity syndrome associated with the
ncreased production of red blood cells; however, only
atients with definite signs of hyperviscosity should be
hlebotomized (4).
Patient education, behavioral modifications, and aware-
ess of potential medical risk factors are important aspects
f management. Patients with ES are at particular risk
Figure 2 The 3 Pathophysiological Pathways in Pulmonary Arte
The pathophysiological pathways illustrated can be targeted using endothelin-recep
derivatives. (Top) a transverse section of a small pulmonary artery (500 m dia
eration and marked medial hypertrophy. Dysfunctional pulmonary-artery endothelia
with an increased production of endothelin-1, which promotes vasoconstriction and
denote an increase in the intracellular concentration; minus signs denote a blocka
tion. Reproduced, with permission, from Humbert et al. (8). Copyright © 2004 Mas
phate; cGMP  cyclic guanosine monophosphate.uring surgery, anesthesia, dehydration, chest infection, tregnancy, high altitude, and intravenous lines (4,6). Pa-
ients are advised to avoid strenuous exercise and competi-
ive sports (6), although light exercise may be beneficial.
Heart–lung transplantation or lung transplantation with
urgery to correct the cardiac defect are options for some
atients with severe ES (16). Transplant surgery is, how-
ver, associated with high perioperative mortality (17).
urvival rates for ES patients are similar to those reported in
on-ES recipients (18,19). The prolonged survival of pa-
ients with ES compared with IPAH complicates the
ecision of whether or not to list ES patients for transplant
urgery. Given the paucity of suitable donor organs, the
mall number of suitable recipients, and prognosis following
ransplantation, any means to delay the need for heart-lung
ypertension
tagonists, nitric oxide, phosphodiesterase type-5 inhibitors, and prostacyclin
from a patient with severe pulmonary arterial hypertension shows intimal prolif-
(blue) exhibit decreased production of prostacyclin and endogenous nitric oxide,
eration of smooth-muscle cells in the pulmonary arteries (red). Plus signs
a receptor, inhibition of an enzyme, or a decrease in the intracellular concentra-
setts Medical Society. All rights reserved. cAMP  cyclic adenosine monophos-rial H
tor an
meter)
l cells
prolif
de of
sachuransplantation in ES patents is advantageous. A recent
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PAH in Eisenmenger Syndrome March 3, 2009:733–40etrospective analysis suggested that ES patients who received
ovel, advanced, targeted therapies, including prostacyclin
nalogs and endothelin receptor antagonists, benefitted from
ignificantly longer mean times to death or listing for trans-
lant than patients receiving standard care (20).
Pulmonary artery banding before cardiac surgery may be
ffective in younger patients with CHD but not in older
dults (21,22). The use of flap-valve closure of congenital
efects was reported to gradually decrease pulmonary vas-
ular resistance (PVR) in some patients with large VSDs
ithout unreasonable mortality and morbidity (23,24).
argeted therapies. A number of vascular mediators have
een implicated in the pathophysiology of PAH, including
rostacyclin, thromboxane A2, endothelin-1, and nitric
xide (7). Evidence also is emerging suggesting that PAH-
HD is associated with altered expression of serotonin,
ulmonary potassium channels, and transforming growth
actor beta and its receptors (4). Given the similarities
etween the pulmonary vascular changes observed in ES
nd other forms of PAH (25), disease-targeting therapies
hat have proved successful in IPAH have been investigated
or the management of ES. Demonstrating prognostic
enefit in ES versus IPAH patients is, however, challeng-
ng, given that patients with ES exhibit a more favorable
emodynamic profile and prognosis than those with IPAH.
long-term comparison of prognosis using end points such
s “time to clinical worsening” in treated patients versus
istorical data, therefore, may be needed.
As a precursor to pharmacological therapy, tests for
ulmonary vasoreactivity have an established role in select-
ng appropriate therapy for patients with IPAH (16,26).
lthough a proportion of patients with PAH-CHD are
esponsive to acute vasodilator testing with nitric oxide
27,28), this response is generally only minimal. Available
reatment guidelines have been derived primarily from
Figure 3 Change From Baseline in 6-Min Walk Distance After T
Improvement of 6-min walk distance in the bosentan group compared with the
placebo group. Reproduced, with permission, from Galiè et al. (25). TE  treatmetudies in IPAH and PAH associated with connective tissue tisease (16,26); therefore, care should be taken in extrapo-
ating data for patients with ES.
NDOTHELIN RECEPTOR ANTAGONISTS. Endothelin-1 plays
major role in the structural and functional abnormalities in
he pulmonary vasculature and in the progression of PAH-
HD and ES. The authors of several small-scale, open-
abel studies with the oral dual endothelin receptor antag-
nist, bosentan, suggested that efficacy in functional class,
xygen saturation, clinical status, and pulmonary hemody-
amics was possible in patients with ES (29–31). The
ouble-blind, placebo-controlled BREATHE-5 (Bosentan
andomized Trial of Endothelin Antagonist Therapy-5)
tudy, the only such study in patients with ES, demon-
trated that bosentan significantly reduced PVR and im-
roved exercise capacity versus placebo (Fig. 3) (25). Bosen-
an was well tolerated and did not adversely affect systemic
rterial oxygen saturation (25). A 24-week, open-label,
ollow-up study demonstrated further improvements in
xercise capacity (Fig. 4) and functional class (32). A post
oc analysis of patient subgroups with ASDs, VSDs, or
oth ASDs and VSDs showed no changes in efficacy or
ystemic pulse oximetry between these patient subgroups
33). Most, but not all, long-term data suggest that clinical
mprovements observed in ES patients treated with bosen-
an can be maintained for at least 2 years, without safety or
olerability issues (34–39).
A retrospective review of 14 patients with ES treated with
he single endothelin receptor antagonist, sitaxsentan,
howed evidence for improvements in the ratio of PVR to
ystemic vascular resistance with no risk of significant
ecreases in resting oxygen saturation (40). Further inves-
igation of the potential benefits of sitaxsentan is warranted.
HOSPHODIESTERASE TYPE-5 INHIBITORS. To date, there
ave been limited studies in which phosphodiesterase
ent With Bosentan or Placebo
ct.reatm
nt effeype-5 inhibitors were used in patients with ES. During a
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March 3, 2009:733–40 PAH in Eisenmenger Syndromerospective, open-label trial of sildenafil, significant im-
rovements in functional class, oxygen saturation, and
ardiopulmonary hemodynamics were observed after 6
onths. Improved exercise capacity (Fig. 5) and reduced
yanosis, with few significant side effects, also were
bserved (41).
Other small studies of phosphodiesterase type-5 inhibi-
ors, alone and in combination with prostanoids, have
hown improvements in exercise capacity, functional class,
nd hemodynamic parameters without safety issues (42–47).
lthough these data increase confidence in the potential safety
nd efficacy of phosphodiesterase type-5 inhibitors in ES, their
alue is limited by the small size of the studies and method-
logical shortfalls. Ultimately, these encouraging efficacy data
equire validation by large, randomized, placebo-controlled
rials. Currently, patients are being recruited to participate
n such a trial in Germany.
Figure 4 Bosentan Improves Exercise Capacity in Patients Wit
Improvement of 6-min walk distance in patients who received bosentan compared
(32). BREATHE-5  Bosentan Randomized Trial of Endothelin Antagonist Therapy-5
the mean.
Figure 5 Effects of Sildenafil on World Health Organization Fun
Improvements in World Health Organization functional class and 6-min walk distan
with sildenafil in patients with Eisenmenger syndrome (ES). Reproduced, with permROSTACYCLIN AND PROSTACYCLIN ANALOGS. Data on pro-
tanoid therapy in patients with ES are limited to case
eports and small studies (43,48–57). Continuous intrave-
ous epoprostenol was reported to significantly improve
unctional class, oxygen saturation, and exercise capacity and
o decrease PVR in 8 patients with ES after 3 months of
herapy (49). The potential benefits and risks of potent
re-operative vasodilator therapy also have been illustrated
n case studies in which continuous prostacyclin improved
emodynamics sufficiently to enable ES patients with ASD
o undergo surgical repair of the cardiac lesion (50,51). The
se of prostanoids in similar “inoperable cases” merits
urther investigation.
Safety of continuous prostanoid therapy is an impor-
ant issue, particularly with respect to increases in SVR
nd PVR, reduced arterial oxygen, and long-term cath-
ter use (49,52). Inhaled and oral prostanoids offer
atients who received placebo. Reproduced, with permission, from Gatzoulis et al.
Eisenmenger syndrome; OLE  open-label extension; SEM  standard error of
al Class and 6-Min Walk Distance in Patients With ES
r treatment
, from Chau et al. (41).h ES
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PAH in Eisenmenger Syndrome March 3, 2009:733–40dvantages over epoprostenol in terms of the safety of
ong-term administration, but their efficacy and safety
as not been comprehensively investigated in patients
ith ES.
uture Aspects
n recent years, advances in targeted therapies for PAH have
hallenged the dogma that ES is a stable disease, not
menable to treatment (25). In the future, surgical and other
herapeutic approaches aimed at reversing vascular remod-
ling and regenerating the pulmonary microvasculature may
e of benefit to our understanding of ES and the optimal
anagement of ES.
Early data suggest that the repair of systemic-to-
ulmonary shunts during childhood may be sufficient to
everse the development of pulmonary vascular disease for
ome patients (58). In other patients, PAH may develop
ven after closure of a septal defect and may result from an
ncreased burden on the right ventricle due to remodeling of
he pulmonary vasculature before surgery (59). Not all
atients with CHD and particularly ASD, corrected or
therwise, develop PAH, and some may exhibit a genetic
redisposition. Research is ongoing to identify those pa-
ients at greatest likelihood of developing pulmonary vascu-
ar disease.
Recent studies in animal models of PAH have demonstrated
eversibility of vascular remodeling in response to long-term
loprost inhalation (60), inhibition of phosphodiesterase-1
61), activation of soluble guanylate cyclase (62), and
ene transfer of angiogenic factors (63). The reversal of
onocrotaline-induced PAH and prolonging of survival using
ene therapy targeting survivin, an inhibitor of apoptosis, also
as been shown in a pre-clinical rodent model (64).
Imatinib, a selective antagonist of the platelet-derived
rowth factor receptor, was effective in the case of a single
atient with severe treatment-refractory familial PAH (65),
uggesting that such antiproliferative drugs may reverse
ulmonary vascular remodeling, thus alleviating pulmonary
ypertension. Treatment with the use of vasoactive intesti-
al peptide also may elicit beneficial effects in PAH (66) and
arrants further investigation.
Increased levels of endothelin-1 produced by the pulmo-
ary vascular endothelium may contribute to systemic dys-
unction in PAH-CHD, although the clinical relevance of
his is unclear in ES (67). Whether current PAH therapies
argeting endothelin-1 can improve systemic circulation,
nd other complications in ES, remains to be elucidated.
The use of combinations of targeted oral therapies for the
reatment of PAH is becoming increasingly commonplace,
nd benefits of early diagnosis and treatment of PAH
ecently have become apparent (68,69). Further investiga-
ion will be needed to elucidate the benefits of these novel
pproaches in ES and the optimal time for initiating
reatment.
1onclusions
isenmenger syndrome is a severe and devastating condi-
ion that is associated with considerable morbidity and
ortality. The identification of pathophysiological similar-
ties between PAH and ES has led to the evaluation of
argeted therapies, including endothelin receptor antago-
ists, phosphodiesterase type-5 inhibitors, prostacyclin, and
rostacyclin analogs, in patients with ES. Improvements in
xercise capacity, functional class, and hemodynamics with-
ut compromising oxygen saturation using these treatments
ave challenged the notion that ES is a stable disease, not
menable to treatment. Continued research to quantify the
alue of earlier intervention, combined regimens of targeted
herapies, and the potential to reverse pulmonary vascular
emodeling in PAH-CHD is warranted.
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